Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336982 · ClinicalTrials.gov registry record · Phase 1
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT04336982 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 22 participants.
The verdict
NCT04336982, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Gilteritinib
- DRUG CC-90009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2020-08-05 |
| Est. Completion | 2024-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04336982
The ClinicalTrials.gov registry entry for NCT04336982 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Venetoclax is the first listed.
NCT04336982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04336982 about?
NCT04336982 is a clinical study titled "A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia". CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute myeloid leukemia (AML).
What is the current status of trial NCT04336982?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2020-08-05. Estimated completion is 2024-04-05.
What interventions are being tested in trial NCT04336982?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Gilteritinib (DRUG), CC-90009 (DRUG).
Who is sponsoring clinical trial NCT04336982?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.